32715279|t|Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale.
32715279|a|BACKGROUND: Preclinical studies, clinical trials, and reviews suggest increasing 3',5'-cyclic adenosine monophosphate (cAMP) and 3',5'-cyclic guanosine monophosphate (cGMP) with phosphodiesterase inhibitors is disease-modifying in Alzheimer's disease (AD). cAMP/protein kinase A (PKA) and cGMP/protein kinase G (PKG) signaling are disrupted in AD. cAMP/PKA and cGMP/PKG activate cAMP response element binding protein (CREB). CREB binds mitochondrial and nuclear DNA, inducing synaptogenesis, memory, and neuronal survival gene (e.g., brain-derived neurotrophic factor) and peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC1alpha). cAMP/PKA and cGMP/PKG activate Sirtuin-1, which activates PGC1alpha. PGC1alpha induces mitochondrial biogenesis and antioxidant genes (e.g.,Nrf2) and represses BACE1. cAMP and cGMP inhibit BACE1-inducing NFkappaB and tau-phosphorylating GSK3beta. OBJECTIVE AND METHODS: We review efficacy-testing clinical trials, epidemiology, and meta-analyses to critically investigate whether phosphodiesteraseinhibitors prevent or treat AD. RESULTS: Caffeine and cilostazol may lower AD risk. Denbufylline and sildenafil clinical trials are promising but preliminary and inconclusive. PF-04447943 and BI 409,306 are ineffective. Vinpocetine, cilostazol, and nicergoline trials are mixed. Deprenyl/selegiline trials show only short-term benefits. Broad-spectrum phosphodiesterase inhibitor propentofylline has been shown in five phase III trials to improve cognition, dementia severity, activities of daily living, and global assessment in mild-to-moderate AD patients on multiple scales, including the ADAS-Cogand the CIBIC-Plus in an 18-month phase III clinical trial. However, two books claimed based on a MedScape article an 18-month phase III trial failed, so propentofylline was discontinued. Now, propentofylline is used to treat canine cognitive dysfunction, which, like AD, involves age-associated wild-type Abeta deposition. CONCLUSION: Phosphodiesterase inhibitors may prevent and treat AD.
32715279	33	52	Alzheimer's Disease	Disease	MESH:D000544
32715279	221	257	3',5'-cyclic adenosine monophosphate	Chemical	-
32715279	259	263	cAMP	Chemical	-
32715279	269	305	3',5'-cyclic guanosine monophosphate	Chemical	-
32715279	307	311	cGMP	Chemical	-
32715279	371	390	Alzheimer's disease	Disease	MESH:D000544
32715279	392	394	AD	Disease	MESH:D000544
32715279	397	401	cAMP	Chemical	-
32715279	429	433	cGMP	Chemical	-
32715279	452	455	PKG	Gene	5592
32715279	484	486	AD	Disease	MESH:D000544
32715279	488	492	cAMP	Chemical	-
32715279	501	505	cGMP	Chemical	-
32715279	506	509	PKG	Gene	5592
32715279	674	707	brain-derived neurotrophic factor	Gene	403461
32715279	713	780	peroxisome proliferator-activated receptor-gamma coactivator-1alpha	Gene	479127
32715279	794	798	cAMP	Chemical	-
32715279	807	811	cGMP	Chemical	-
32715279	812	815	PKG	Gene	5592
32715279	825	834	Sirtuin-1	Gene	489012
32715279	954	959	BACE1	Gene	489390
32715279	961	965	cAMP	Chemical	-
32715279	970	974	cGMP	Chemical	-
32715279	983	988	BACE1	Gene	489390
32715279	1031	1039	GSK3beta	Gene	478575
32715279	1219	1221	AD	Disease	MESH:D000544
32715279	1232	1240	Caffeine	Chemical	MESH:D002110
32715279	1245	1255	cilostazol	Chemical	MESH:D000077407
32715279	1266	1268	AD	Disease	MESH:D000544
32715279	1275	1287	Denbufylline	Chemical	MESH:C043898
32715279	1292	1302	sildenafil	Chemical	MESH:D000068677
32715279	1367	1378	PF-04447943	Chemical	MESH:C572323
32715279	1383	1393	BI 409,306	Chemical	-
32715279	1411	1422	Vinpocetine	Chemical	MESH:C013983
32715279	1424	1434	cilostazol	Chemical	MESH:D000077407
32715279	1440	1451	nicergoline	Chemical	MESH:D009530
32715279	1470	1478	Deprenyl	Chemical	MESH:D012642
32715279	1479	1489	selegiline	Chemical	MESH:D012642
32715279	1571	1586	propentofylline	Chemical	MESH:C032114
32715279	1649	1657	dementia	Disease	MESH:D003704
32715279	1738	1740	AD	Disease	MESH:D000544
32715279	1741	1749	patients	Species	9606
32715279	1946	1961	propentofylline	Chemical	MESH:C032114
32715279	1985	2000	propentofylline	Chemical	MESH:C032114
32715279	2018	2024	canine	Species	9615
32715279	2025	2046	cognitive dysfunction	Disease	MESH:D003072
32715279	2060	2062	AD	Disease	MESH:D000544
32715279	2179	2181	AD	Disease	MESH:D000544
32715279	Negative_Correlation	MESH:C032114	MESH:D003072
32715279	Association	MESH:D000544	5592
32715279	Negative_Correlation	MESH:D002110	MESH:D000544
32715279	Negative_Correlation	MESH:C032114	MESH:D003704
32715279	Positive_Correlation	489012	5592
32715279	Negative_Correlation	MESH:C032114	MESH:D000544
32715279	Negative_Correlation	MESH:D000077407	MESH:D000544

